February 12, 2024

Unlearn uses AI in Clinical Research

Unlearn, an AI company, raised $50M in Series C funding led by Altimeter Capital. They
partner with pharma companies, biotechs, and academics to optimize clinical trials.
Unlearn uses advanced AI models to create digital twins of each clinical trial participant before
they are randomized. The digital twin forecasts health outcomes for that participant under
placebo.
This enables TwinRCTs - smaller control groups with more patients getting the experimental
treatment. TwinRCTs reduce timelines and accelerate research.
The AI-powered digital twins address key challenges like long timelines, slow enrollment, and
patients not wanting a placebo.
By simulating placebo response, the technology reduces the control group size needed to
power trials.
Unlearn has regulatory approval in Europe and alignment with FDA guidance. They could
transform clinical research by bringing novel treatments to market faster. This seems
revolutionary.